Sun Pharmaceutical Industries Limited: Business Overview, Financials & Competitive Analysis
Sun Pharmaceutical Industries Limited scores 7/10 on the AskCyborg Cyborg Score (Solid). Well-positioned global specialty generics leader with strong R&D investment and M&A momentum, but earnings headwinds require near-term recovery demonstration. Current market capitalization of Sun Pharmaceutical Industries is $45.1B with strong global scale and diversification. However, earnings have been going backwards lately while most other companies have been seeing.
What is Sun Pharmaceutical Industries Limited's industry? Sun Pharmaceutical Industries Limited (sunpharma.com) operates in Specialty Generic Pharmaceuticals & Biopharmaceuticals. AskCyborg classifies Sun Pharmaceutical Industries Limited under Specialty Generic Pharmaceuticals & Biopharmaceuticals in its company registry.
Sun Pharma is the fourth largest global specialty generic pharmaceutical company with a presence in more than 100 countries. With global revenue of US$ 6.2 billion, the company operates 41 manufacturing facilities, pr...
Cyborg Score thesis
Well-positioned global specialty generics leader with strong R&D investment and M&A momentum, but earnings headwinds require...
Read the full analyst-debate transcript →Get the Latest Sun Pharmaceutical Industries Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSun Pharmaceutical Industries Limited Overview
Pro stress-test →Sun Pharma is the fourth largest global specialty generic pharmaceutical company with a presence in more than 100 countries. With global revenue of US$ 6.2 billion, the company operates 41 manufacturing facilities, providing high-quality medicines to more than 100 countries across the globe. Sun Pharma delivers a diversified portfolio spanning generics, specialty therapeutics, and consumer healthcare.
Strategic Profile
Pro stress-test →From humble beginnings in 1983, Sun Pharma has grown into a leading specialty generic company worldwide and the No. 1 pharmaceutical company in India. The company has pursued strategic growth through significant acquisitions, including Ranbaxy, Taro Pharmaceuticals, and the March 2025 acquisition of Checkpoint Therapeutics. Sun Pharma invests 6–8% of global revenues annually into Research and Development with a team of over 2,900 R&D personnel, strengthening its position in complex and differentiated formulations.
Competitive Landscape
Pro stress-test →Sun Pharma is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. Key competitors include other major generics manufacturers in the Indian and global markets such as Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, and Cipla. The company maintains competitive advantages through its specialized formulation capabilities, dermatology portfolio strength, and substantial R&D investment.
Industry Context
Sun Pharmaceutical Industries Limited operates in Specialty Generic Pharmaceuticals & Biopharmaceuticals.
Key facts
Founded: 1983 · Headquarters: Mumbai, India · Employees: 38000+ · Revenue: $6.2B · Market cap: $45.1B